NTLA: One-Time CRISPR Treatment Shows 97% Attack-Free Rate for Hereditary Angioedema Patients
Groundbreaking Results: Lonvo-z Delivers Durable Relief in HAE
Intellia Therapeutics (NASDAQ: NTLA) has released encouraging new data for its CRISPR-based gene editing therapy, lonvoguran ziclumeran (lonvo-z), in patients with hereditary angioedema (HAE). According to a pooled analysis from Phase 1/2 trials, a one-time 50 mg dose led to 97% of treated patients being both attack-free and off long-term prophylaxis for up to 32 months, setting a potential new standard for disease management.
Pooled Phase 1/2 Data Shows High Attack-Free Rates and Sustained Kallikrein Suppression
Out of 32 adults with HAE types I or II who received the 50 mg dose:
| Patient Subgroup | Number of Patients | Attack-Free & LTP-Free | Duration |
|---|---|---|---|
| All 50 mg Dose (Pooled) | 32 | 31 (97%) | Up to 32 months |
| Attack-Free & LTP-Free =7 months | 24 | 75% | 7–32 months |
| Initial Phase 2 50 mg Cohort | 11 | 10 | 9 (7–32 months), 1 (<6 months) |
| Mean Kallikrein Reduction | - | 89% at Month 24 | |
These numbers suggest deep, consistent reductions in kallikrein—a key target in HAE pathogenesis—with substantial, long-lasting freedom from HAE attacks and daily therapy.
Safety Profile Remains Strong with Up to Three Years of Follow-Up
The safety data reinforces the therapy’s promise: no new long-term risks were identified with up to three years of follow-up. Most reported adverse events were mild and short-lived, such as infusion-related reactions, fatigue, and headache. No significant liver or blood issues emerged, and a single serious event—a pulmonary embolism in a patient with known risk factors—resolved without lasting harm.
- Most common short-term (=28 days) side effects: infusion reactions, fatigue, headache.
- Long-term follow-up: nasopharyngitis, respiratory infections, mild back pain, arthralgia, and COVID-19 were noted.
- No severe or lasting safety signals reported for patients re-dosed or after 25 mg to 50 mg escalation.
One-Time CRISPR-Based Therapy May Redefine HAE Treatment
Lonvo-z’s clinical performance sets it apart as the first investigational one-time treatment for HAE. Utilizing Nobel Prize-winning CRISPR/Cas9 technology, the therapy works by inactivating the KLKB1 gene—essentially lowering the precursor protein responsible for swelling attacks. Its streamlined single-infusion protocol could eliminate the lifelong burden of current preventive therapies, many of which require ongoing injections or infusions.
What’s Next: Eyes on Phase 3 Readout in 2026
The data come ahead of a pivotal Phase 3 trial (HAELO), which has completed enrollment and is on track for topline results by mid-2026. With robust safety and efficacy thus far, lonvo-z could soon shift the standard of care for HAE if regulatory milestones are met.
Takeaway: CRISPR Therapy Is Edging Closer to Transforming Rare Disease Care
The nearly universal and durable freedom from HAE attacks—combined with a favorable safety profile—suggests lonvo-z may usher in a new era for gene-editing therapeutics. While Phase 3 and regulatory reviews remain, these interim results provide patients and clinicians strong cause for optimism, and the biotech industry a clear signal that one-time, disease-modifying CRISPR treatments are closer to clinical reality.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI